C4 Therapeutics, Inc. (CCCC) Misses Q4 EPS by 188c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Credit Suisse Upgrades C4 Therapeutics (CCCC) to Neutral, 'Improved Outlook w/ Multiple Shots on Goal Post 4Q22 EPS'
February 24, 2023 1:24 PM ESTCredit Suisse analyst Richard Law upgraded C4 Therapeutics (NASDAQ: CCCC) from Underperform to Neutral with a price target of $10.00 (from $12.00).
The analyst comments "CCCC reported 4Q22 financial results on Thursday morning with GAAP EPS of -$0.65. Total collaboration revenues... More
